MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cpcardiol.2026.103409

Медицинская библиотека · Current problems in cardiology · 2026

Efficacy and tolerability of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy: A systematic review and stratified meta-analysis.

Magnano Roberta, Rossi Davide, Saraullo Silvio, Zuardi Vittoria, Pezzi Laura, D'Alleva Alberto, Marino Mario Di, Scollo Claudio, Genovesi Eugenio, Guarracini Stefano, Forlani Daniele, Vitulli Piergiusto, Renda Giulia, Gallina Sabina, Marco Massimo Di

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

AIMS: Although disease-modifying therapies have changed the management of transthyretin amyloid cardiomyopathy (ATTR-CM), supportive heart failure care remains crucial. Patients with ATTR-CM were excluded or underrepresented in randomized trials of sodium-glucose cotransporter-2 inhibitors (SGLT2i), leaving their role in this population uncertain. We performed a systematic review and stratified meta-analysis evaluating their efficacy, safety, and tolerability.

METHODS AND

RESULTS

PubMed/MEDLINE, Scopus, and the Cochrane Library/CENTRAL were searched up to 1 May 2026. The primary endpoint was ATTR-specific HR-based all-cause mortality. For studies enrolling both ATTR and AL amyloidosis, only separable ATTR subcohort estimates were extracted for the primary synthesis; AL estimates were excluded. Risk of bias was assessed using ROBINS-I and certainty of evidence using GRADE. Eighteen studies were included, comprising 12,039 SGLT2i-treated patients and 12,016 comparator patients across all analytic domains, although possible database overlap should be considered. The primary ATTR-specific HR-based synthesis showed an association between SGLT2i therapy and lower all-cause mortality (HR 0.65, 95% CI 0.56-0.76; I²=37.5%; 8 studies). HF-related events were directionally favourable but non-definitive (HR 0.73, 95% CI 0.50-1.06; I²=73.2%; 5 studies). Composite mortality/HF-related outcomes were associated with a lower risk (HR 0.69, 95% CI 0.55-0.85; I²=3.1%; 3 studies). Arrhythmic outcomes were only exploratory. SGLT2i therapy appeared well tolerated, with low pooled rates of definite discontinuation (6.9%), genitourinary events (4.7%), and AKI/renal adverse events (2.3%).

CONCLUSION

Current non-randomized ATTR-specific evidence suggests that SGLT2i therapy in ATTR-CM/ATTR-HF is associated with lower all-cause mortality and acceptable safety and tolerability. Certainty remains low because of observational design, endpoint heterogeneity, heterogeneous background disease-modifying therapy, potential database overlap, and lack of patient-level amyloidosis subtype/stage stratification. Dedicated randomized trials are needed.

Для цитирования: Magnano Roberta, Rossi Davide, Saraullo Silvio, Zuardi Vittoria, Pezzi Laura, D'Alleva Alberto, Marino Mario Di, Scollo Claudio, Genovesi Eugenio, Guarracini Stefano, Forlani Daniele, Vitulli Piergiusto, Renda Giulia, Gallina Sabina, Marco Massimo Di. Efficacy and tolerability of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy: A systematic review and stratified meta-analysis.. Current problems in cardiology. 2026. DOI: 10.1016/j.cpcardiol.2026.103409.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.